Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 173,729 | 213,584 | 132,944 | 307,584 | 713,526 |
| Marketable Securities | 436,296 | 363,625 | 614,818 | 432,612 | 488,007 |
| Receivables | 121,801 | 73,390 | 40,445 | 28,432 | 23,093 |
| Inventories | 45,007 | 33,969 | 26,766 | 16,231 | 13,048 |
| TOTAL | $817,123 | $732,184 | $883,899 | $856,604 | $1,295,304 |
| Non-Current Assets | |||||
| PPE Net | 265,929 | 290,566 | 259,726 | 141,247 | 73,515 |
| Investments And Advances | 135,004 | 199,901 | 148,970 | 293,858 | 165,881 |
| Intangibles | 222,720 | 210,677 | 204,511 | 175,194 | 175,519 |
| Other Non-Current Assets | 62,680 | 57,685 | 48,338 | 55,494 | 49,336 |
| TOTAL | $686,333 | $758,829 | $661,545 | $665,793 | $464,251 |
| Total Assets | $1,503,456 | $1,491,013 | $1,545,444 | $1,522,397 | $1,759,555 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 38,756 | 42,114 | 43,274 | 17,138 | 12,923 |
| Accrued Expenses | 240,973 | 196,486 | 204,678 | 145,555 | 108,491 |
| Other current liabilities | 54,127 | 29,242 | 1,479 | 7,609 | 59,219 |
| TOTAL | $344,153 | $280,437 | $261,210 | $181,368 | $189,609 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 873,948 | 905,104 | 900,073 | 385,162 | 382,265 |
| TOTAL | $904,006 | $935,162 | $931,740 | $418,468 | $415,571 |
| Total Liabilities | $1,248,159 | $1,215,599 | $1,192,950 | $599,836 | $605,180 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 92,501 | 82,336 | 70,217 | 69,385 | 66,949 |
| Common Shares | 92 | 82 | 70 | 69 | 67 |
| Retained earnings | -3,956,844 | -3,387,661 | -2,781,022 | -2,073,601 | -1,619,576 |
| Other shareholders' equity | 3,357 | 647 | -6,573 | -1,404 | 689 |
| TOTAL | $255,297 | $275,414 | $352,494 | $922,561 | $1,154,375 |
| Total Liabilities And Equity | $1,503,456 | $1,491,013 | $1,545,444 | $1,522,397 | $1,759,555 |